Tokai Pharmaceuticals Inc. (Nasdaq: TKAI) will discontinue a late-stage study of its prostate cancer treatment. The stock price collapsed $4.10 to close at $1.10.
Tokai Pharmaceuticals discontinues study
July 26, 2016 at 18:25 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.